期刊
LEUKEMIA & LYMPHOMA
卷 49, 期 4, 页码 629-634出版社
INFORMA HEALTHCARE
DOI: 10.1080/10428190801927510
关键词
chronic myelogenous leukemia; immunotherapy; interferon; imatinib
Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL plays an important role as oncoprotein and also as a molecular and immunogenic target. In fact, several molecular targeted drugs and immunotherapies have been developed for this disease. In the current article, several immuno therapeutic approaches in CML, including interferon-alpha and vaccination, are discussed along with results from clinical trials and the value of such immunotherapies in the imatinib-era.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据